Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “SION”

1,496 pharma patents match "SION" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 1,496
Index total 30,257
Page 41 / 63

Quick answer

This filtered view shows 1,496 pharmaceutical patents matching "SION" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

1,496 results for “SION” · 30,257 patents in full index Clear search

  1. US 8975295

    Modulation of zinc levels to improve tissue properties

    Precision Dermatology, Inc. · Granted Mar 10, 2015 · Expires Mar 5, 2035

    granted

  2. US 8969409

    Treatment for pulmonary hypertension

    United Therapeutics Corporation · Granted Mar 3, 2015 · Expires Feb 26, 2035

    granted

  3. US 8969077

    Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord

    The Regents of the University of California · Granted Mar 3, 2015 · Expires Feb 26, 2035

    granted

  4. US 8962588

    Micro-RNAS that control myosin expression and myofiber identity

    The Board of Regents of the University of Texas System · Granted Feb 24, 2015 · Expires Feb 19, 2035

    granted

  5. US 8962026

    Nanoemulsion therapeutic compositions and methods of using the same

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Feb 24, 2015 · Expires Feb 19, 2035

    granted

  6. US 8957031

    Competitive inhibitors of invariant chain expression and/or ectopic clip binding

    The Regents of the University of Colorado, a Body Corporate · Granted Feb 17, 2015 · Expires Feb 12, 2035

    granted

  7. US 8951968

    Methods of treating depression and other related diseases

    Northwestern University · Granted Feb 10, 2015 · Expires Feb 5, 2035

    granted

  8. US 8951971

    Lymphatic zip codes in tumors and pre-malignant lesions

    The Regents of the University of California · Granted Feb 10, 2015 · Expires Feb 5, 2035

    granted

  9. US 2015038439

    METHOD FOR PREPARING SUSPENSIONS OF LOW-SOLUBILITY MATERIALS

    MACLEOD STEVEN K [US] · Granted Feb 5, 2015 · Expires Jan 31, 2035

    granted

  10. US 8946176

    Compositions and methods for inhibiting expression of RRM2 genes

    Arrowhead Research Corporation · Granted Feb 3, 2015 · Expires Jan 29, 2035

    granted

  11. US 8940690

    Synthetic conjugates and uses thereof

    The United States of America as represented by NIH Division of Extramural Inventions and Technology Resources (DEITR) · Granted Jan 27, 2015 · Expires Jan 22, 2035

    granted

  12. US 8940701

    Compounds for, and methods of, treating cancer and inhibiting invasion and metastases

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Jan 27, 2015 · Expires Jan 22, 2035

    granted

  13. US 8933216

    Immunosuppression compound and treatment method

    Sarepta Therapeutics, Inc. · Granted Jan 13, 2015 · Expires Jan 8, 2035

    granted

  14. US 8927233

    Fusion polypeptides capable of activating receptors

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 6, 2015 · Expires Jan 1, 2035

    granted

  15. US 8921097

    Methods for expression and purification of immunotoxins

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Dec 30, 2014 · Expires Dec 25, 2034

    granted

  16. US 8920800

    Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins

    Five Prime Therapeutics, Inc. · Granted Dec 30, 2014 · Expires Dec 25, 2034

    granted

  17. US 8911728

    High-affinity fully functional soluble single-domain human CD4, antibodies, and related fusion proteins

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Dec 16, 2014 · Expires Dec 11, 2034

    granted

  18. US 8912316

    Compositions and methods for inhibiting expression of CD45 gene

    The Government of the United States, as Respresented by the Secretary of the Army · Granted Dec 16, 2014 · Expires Dec 11, 2034

    granted

  19. US 8907053

    Immunosuppression modulating compounds

    Aurigene Discovery Technologies Limited · Granted Dec 9, 2014 · Expires Dec 4, 2034

    granted

  20. US 8901095

    Selective inhibition of polyglutamine protein expression

    The Board of Regents of the University of Texas System · Granted Dec 2, 2014 · Expires Nov 27, 2034

    granted

  21. CA 2912973

    BIOMARQUEURS D'EXPRESSION DE GENES ET LEUR UTILISATION POUR DES APPLICATIONS DIAGNOSTIQUES ET PRONOSTIQUES CHEZ DES PATIENTS NECESSITANT EVENTUELLEMENT UN TRAITEMENT FAISANT INTER VENIR UN INHIBITEUR DE HDAC

    4SC AG [DE] · Granted Nov 27, 2014 · Expires Nov 22, 2034

    granted

  22. US 8889644

    GNAQ targeted dsRNA compositions and methods for inhibiting expression

    Alnylam Pharmaceuticals, Inc. · Granted Nov 18, 2014 · Expires Nov 13, 2034

    granted

  23. US 8883161

    Fusion polypeptide against EB virus-induced tumor and colicin Ia mutant

    PROTEIN DESIGN LAB, LTD. · Granted Nov 11, 2014 · Expires Nov 6, 2034

    granted

  24. US 8883996

    Methods and compositions for the specific inhibition of gene expression by double-stranded RNA

    INTEGRATED DNA TECHNOLOGIES, INC. · Granted Nov 11, 2014 · Expires Nov 6, 2034

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.